Home >> Life Sciences >> Healthcare

Influenza Market (H1N1 Vaccines and Others) by Product (Influenza Vaccines and Influenza Drugs): Global Industry Perspective, Comprehensive Analysis and Forecast 2014 - 2020

Published: Oct-2015 | Format: PDF | Zion | Number of pages: 112 | Code: MRS - 36077

The report provides estimate, forecast and analysis for the influenza market over a global and regional level. The influenza market is in terms of revenue (USD million), for the period from 2015 to 2020, whereas study provides significant information related to market. The study also offers important market dynamics such as Market size, production forecasts along with key factors driving and restraining the market. Additionally, the report includes the study of opportunities, which are available in the influenza market across global level.

This report provides decisive view on the influenza market to the readers, which describes industry growth rate, industry capacity, and industry structure. Study of Porter’s Five Forces model for the influenza market helps to understand competitive landscape in the market. Some additional parameters such as attractiveness analysis, wherein product segments are benchmarked based on their market size and growth rate, in which different segments are benchmarked related to their market size, growth rate and general attractiveness.

The research provides influenza market bifurcating it into influenza viruses and its vaccines. Influenza viruses includes influenza type A, influenza type B, influenza type C. All the market distribution on products and application has been analyzed based on present and future trends and the market is estimated from 2015 to 2020.

The report provides global scenario of Influenza Market comprehensive overview and market figures. Moreover, study gives the current and expected demand for main region including Americas, EMEA and Asia Pacific. The report provides detailed bifurcation of global influenza market on the basis of products type such as influenza vaccines and influenza drugs. Similar bifurcation has been provided for the individual region.  

The report covers detailed competitive scenario including the market share and company overviews, financial revenues of the key participants to develop their positions in the global market. Some key players in this market include AstraZeneca, F. Hoffmann-La Roche, GlaxoSmithKline, Novartis, Sanofi-Pasteur and others.

This report segments the global market as follows:

  • Influenza Market - Product Segment Analysis
  • Influenza Vaccines
  • Influenza Drugs

Influenza Market – Regional Analysis

  • Americas
  • EMEA (Europe, Middle East and Africa)
  • Asia Pacific
  • Chapter 1. Preface
    • 1.1. Report description and scope
    • 1.2. Research methodology
      • 1.2.1. Market research process
    • 1.3. List of abbreviations
  • Chapter 2. Executive Summary
    • 2.1. Global Influenza Market Revenue, 2014 - 2020 (USD Billion)
    • 2.2. Influenza Market: Snapshot
  • Chapter 3. Influenza Market – Market Dynamics
    • 3.1. Introduction
    • 3.2. Introduction and Classification
      • 3.2.1. Seasonal Influenza
      • 3.2.2. Pandemic Influenza
      • 3.2.3. Zoonotic or Variant Influenza
    • 3.3. Influenza Season
    • 3.4. Geographical Distribution
    • 3.5. Market Drivers
      • 3.5.1. Increase in Awareness Regarding Influenza
      • 3.5.2. Increase in Industry-Academia Collaborations
      • 3.5.3. Global Action Plan for Influenza Vaccines
    • 3.6. Market Restraints
    • 3.7. Market Trends
    • 3.8. Porter’s Five Forces Analysis
  • Chapter 4. Market Landscape
    • 4.1. Buying Criteria
    • 4.2. Vendor landscape
      • 4.2.1. competitive Scenario
        • Key News
        • M&A’s
      • 4.2.2. Market Share Analysis
        • Sanofi Pasteur
        • F. Hoffmann-La Roche
        • GlaxoSmithKline
        • AstraZeneca
        • Novartis
      • 4.2.3. Other Prominent Vendors
  • Chapter 5. Market Segmentation by Type of Influenza Virus
    • 5.1. Influenza Type A Viruses
    • 5.2. Influenza Type B Viruses
    • 5.3. Influenza Type C Viruses
  • Chapter 6. Global H1N1 Vaccines Market
    • 6.1. Market Share
    • 6.2. Market Segmentation
    • 6.3. Market Size and Forecast
    • 6.4. Geographical Segmentation
  • Chapter 7. Market Segmentation by Product Type
  • Chapter 8. Global Influenza Drugs Market
    • 8.1. Market Segmentation
      • 8.1.1. M2 Protein inhibitors
      • 8.1.2. Neuraminidase Inhibitors
    • 8.2. Market Size and Forecast
    • 8.3. Key Approved Influenza Drugs
      • 8.3.1. In US
      • 8.3.2. In EU
  • Chapter 9. Global Influenza Vaccines Market
    • 9.1. Market Segmentation
    • 9.2. Market Size and Forecast
    • 9.3. WHO Recommendation
    • 9.4. Key Approved Influenza Vaccines
      • 9.4.1. In US
      • 9.4.2. In EU
  • Chapter 10. Geographical Segmentation
  • Chapter 11. Company Profiles
    • 11.1. AstraZeneca
      • 11.1.1. Key Facts
      • 11.1.2. Business Description
      • 11.1.3. Business Segmentation
      • 11.1.4. Business Strategy
      • 11.1.5. Business Segmentation by Revenue
      • 11.1.6. Revenue Comparison 2011-2013
      • 11.1.7. Geographical Segmentation by Revenue
      • 11.1.8. Key Development
      • 11.1.9. SWOT Analysis
    • 11.2. F. Hoffmann-La Roche
      • 11.2.1. Key Facts
      • 11.2.2. Business Description
      • 11.2.3. Business Segmentation by Revenue
      • 11.2.4. Geographical Segmentation by Revenue
      • 11.2.5. Business Strategy
      • 11.2.6. Key Development
      • 11.2.7. SWOT Analysis
    • 11.3. GlaxoSmithKline
      • 11.3.1. Key Facts
      • 11.3.2. Business Description
      • 11.3.3. Business Segmentation
      • 11.3.4. Business Segmentation by Revenue
      • 11.3.5. Geographical Segmentation by Revenue
      • 11.3.6. Pipeline Products
      • 11.3.7. Business Strategy
      • 11.3.8. Key Development
      • 11.3.9. SWOT Analysis
    • 11.4. Novartis
      • 11.4.1. Key Facts
      • 11.4.2. Business Description
      • 11.4.3. Business Segment at ion by Revenue 2013 103
      • 11.4.4. Business Segmentation Revenue Comparison 2012-2013
      • 11.4.5. Geographical Segmentation by Revenue
      • 11.4.6. Business Strategy
      • 11.4.7. Key Development
      • 11.4.8. SWOT Analysis
    • 11.5. Sanofi Pasteur
      • 11.5.1. Key facts
      • 11.5.2. Business Description
      • 11.5.3. Business Strategy
      • 11.5.4. Key Development
      • 11.5.5. SWOT Analysis

List of Tables

1.    Global Influenza Market Segments 2013-2020

List of Figures

1.    Market Research Methodology
2.    Percentage of Influenza Positive Cases and Virus Subtypes for Week 32, 2014    
3.    Number of Specimens Tested Positive for Influenza by Sub type (Worldwide)    
4.    Number of Specimens Tested Positive e for I influenza by Subtype in Northern Hemisphere    
5.    Number of Specimens Tested Positive for Influenza by Subtype in Southern Hemisphere    
6.    Global Influenza Market 2013-2020 (U S$ million)    
7.    Global Influenza Market Segmentation by Type of Influenza Virus    
8.    Share of H1N1 Vaccines in Global Influenza Market 2013    33
9.    Revenue Share of H1N1 Vaccines in Global Influenza Vaccines Market 2013    
10.    Global H1N1 Vaccines Market Segmentation by Route of Administration    
11.    Global H1N1 Vaccines Market 2013-2020 (U S$ million)    
12.    Global H1N1 Vaccines Market by Geographical Segmentation 2013    
13.    Global Influenza Market Segmentation by Product Type    
14.    Global Influenza Market Segmentation by Product Type 2013    
15.    Global Influenza Market Segmentation by Product Type 2020    
16.    Global Influenza Market Segmentation by Application 2013-2020 (U S$ million)    
17.    YoY Growth Rate of Global Influenza Market Segments 2013-2020    
18.    Global Influenza Drugs Market 2013-2020 (U S$ million)    
19.    Global Influenza Vaccines Market Segmentation by Route of Administration    
20.    Global Influenza Vaccines Market 2013-2020 (U S$ million)    
21.    Global Influenza Market by Geographical Segmentation 2013    
22.    Global Influenza Market Share Analysis 2013    
23.    Sanofi Pasteur's Influenza Vaccine Geographical Segmentation 2013    
24.    Sales of Tami flu by Geographical Segmentation 2013    
25.    Sales of Fluarix/FluLav al by Geographical Segmentation 2013    
26.    Sales of Flu Mist/Fluenz by Geographical Segmentation 2013    
27.    AstraZeneca: Business Segmentation    
28.    AstraZeneca: Business Segmentation by Revenue 2013    
29.    AstraZeneca: Revenue by Business Segmentation 2011-2013 (US$ billions)    
30.    AstraZeneca: Geographical Segmentation by Revenue 2013    
31.    F. Hoffmann-La Roche: Business Segmentation by Revenue 2012 and 2013
32.    F. Hoffmann-La  Roche:  Revenue  of  Pharmaceuticals  Division  by Geographical Segmentation 2013   
33.    F. Hoffmann-La Roche: Revenue of Diagnostics Division by Geographical Segmentation 2013    
34.    GlaxoSmithKline: Business Segmentation by Revenue 2012 and 2013 (US$ billion)    
35.    GlaxoSmithKline: Geographical Segmentation by Sales 2013    
36.    GlaxoSmithKline: Pipeline Products    
37.    Novartis AG: Business Segmentation by Revenue 2013    
38.    Novartis AG: Business Segmentation by Revenue 2012 and 2013 (U S$ million)    
39.    Novartis AG: Geographical Segmentation by Sales 2013

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

Zion Research uses the synergy of combination of both primary research and secondary research for its research reports. For this study, we have conducted extensive primary research, wherein we have conducted in-depth interviews of the key opinion leader of this industry. Primary research make up for the biggest chunk of our data sources in addition to secondary research.

We referred to product literature of leading industry participants, annual reports, press releases, government publications, and other relevant sources for data collection and analysis thereof. Secondary research also includes a search of recent trade journals, technical writing, internet sources, and statistical data from government websites, trade associations and agencies.  

Zion Research has collected key data related to the Influenza Market and analyzed these data using a variety of methods. The market dynamics have been ascertained following a detailed study of the micro, meso, and macroeconomic indicators of the market.

This report is based on in-depth qualitative and quantitative analyses of the Influenza Market. The quantitative analysis involved the application of various projection and sampling techniques. The qualitative analysis involved primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes were validated through experts' opinions.

Primary Research

We conduct primary interviews with industry participants and commentators on an ongoing basis to validate data and analysis. A typical research interview fulfills the following functions:

  • Provides firsthand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
  • Helps in validating and strengthening the secondary research findings
  • Further develops the analysis team’s expertise and market understanding
  • Primary research involves e-mail interactions, telephonic interviews as well as face-to-face interviews for each market, category, segment and sub-segment across geographies

Participants who typically partake in such a process include, but are not limited to:

  • Industry participants: CEOs, VPs, marketing/product managers, market intelligence managers and national sales managers
  • Purchasing managers, technical personnel, distributors and resellers
  • Outside experts: Investment bankers, valuation experts and research analysts specializing in specific markets

Key opinion leaders specializing in different areas corresponding to different industry verticals

Secondary Research

Secondary research sources that are typically referred to include, but are not limited to:

  • Company websites, annual reports, financial reports, broker reports, investor presentations and SEC filings
  • IDC and other relevant magazines
  • Internal and external proprietary databases, and relevant patent and regulatory databases
  • National government documents, statistical databases and market reports

News articles, press releases and webcasts specific to companies operating in the market

Based on the research results and technical insights thus gathered, Zion research analysts have provided a comprehensive analysis of the varied aspects of the market. The impact of global economic conditions and other macroeconomic indicators was also considered when assessing the market.


Where no hard data is available, we use models and estimates to produce comprehensive data sets. A rigorous methodology is adopted, wherein the available hard data is cross-referenced with the following data types to produce estimates:

  • Demographic data: Population split by segments
  • Macroeconomic indicators: GDP, PPP, Per Capita Income, etc.
  • Industry indicators: Expenditure, technology stage and infrastructure, sector growth and facilities
  • Data is then cross-checked by an expert panel.

Influenza is a infectious disease caused by the influenza viruses namely influenza A, influenza B, influenza C. It’s a contagious disease commonly known as flu. Usually influenza virus spread through the air from sneezes and coughs. Influenza A viruses furthers sub segmented into neuraminidase and hemagglutinin.

Influenza can be classified into seasonal, pandemic and zoonotic or variant. Flu pandemic occurs when new influenza virus A emerged into body. This virus quickly spread disease from one person to another. Currently, H1N1 Influenza is affecting many people in more than 180 countries across the global in 2009. A vaccine made for one year may not be useful in the following year, since the virus evolves rapidly. Antiviral drugs such as the neuraminidase inhibitors oseltamivir among others have been used to treat influenza.  

Increasing awareness regarding influenza is one of the major driving factors for global influenza market. Chances of getting influenza infection are rising across the world owing to lack of awareness about flu and its consequences. Thus, increase in awareness is expected to increase the targeted population for vaccination. Increase in industry-academia collaboration is also expected to boost the global influenza market. Increasing industry support to academic institutes is expected to create synergy of the research expertise of academic institutions with the marketing intelligence of pharmaceutical companies, as well as providing funds to conduct trial studies. Moreover, world health organization (WHO) has also come up with a global action plan for influenza vaccination across the globe.

Influenza Market

However, influenza market is expected to face major challenge from antigenic drift of influenza viruses. Influenza virus continuously evolves at a rapid pace. Additionally, lack of cold storage facilities presents major challenge for the growth of influenza market.

H1N1 vaccines accounts for major chunk of influenza market with around 79% share of the total market in 2014. Influenza market is also segmented based on drugs and vaccines. Vaccines dominated the influenza market with over 80% share of the market in 2014. It is also expected to be the fastest growing market segment during the forecast period. On the basis of regions, global influenza market has been segmented as Americas, EMEA (Europe, Middle East and Africa) and Asia Pacific. Americas dominated the global market with around 60% share of the global market in 2014. Americas was followed by EMEA and Asia Pacific respectively.

Some of the key industry participants in global influenza market include AstraZeneca, F. Hoffmann-La Roche, GlaxoSmithKline, Novartis, Sanofi-Pasteur and others. Global influenza market is led by top five companies including AstraZeneca, F. Hoffmann-La Roche, GlaxoSmithKline, Novartis, Sanofi-Pasteur. This five companies accounts for over two third shares of the global market.

Single User | $(USD)4199 View Pricing